Preventing Deep Vein Thrombosis (DVT)
More people die from blood clotting complications annually than breast cancer, HIV/AIDS and road traffics accidents combined. It is estimated that nearly 2 million people in the United States are diagnosed with a DVT each year. In addition, more than 50% of all hospitalized patients are at risk of developing a DVT. The Venowave™ VW5 enables an active lifestyle while delivering impressive clinical efficacy across a class of diseases that have developed as a result of chronic venous insufficiency (CVI), and notably preventing Venous Thromboembolism (VTE).
- Chronic Venous Insufficiency (CVI)
- Varicose Veins
- Post Thrombotic Syndrome (PTS)
- Peripheral Arterial Disease (PAD)
Wound Healing Interventions
Approximately 6 million people in the United States suffer from chronic, non-healing wounds, and this number is growing steadily. It is estimated that 25% of diabetics will develop a foot ulcer and 70% of those patients will suffer from a recurrent wound within 5 years. If wounds are left untreated, it can lead to amputation. Every 30 seconds a lower limb is amputated somewhere in the world because of a diabetic wound. The Venowave can help arterial, venous and diabetic wounds. By increasing blood flow a higher level of oxygen is brought to wound sites, promoting faster healing and helping to fend off potential amputations.
Early test results are good. I concur - the results were totally unexpected (and dramatic).–Robert G. Frykberg, DPM, MPH Chief, Podiatry:Phoenix VA Healthcare System
It is definitely exciting to have a potential new option to treat patients with peripheral arterial disease, because we don't have that many options!–Dr. Sonia Anand, Associate Professor of Medicine at McMaster University
I've got mobility again. It's a miracle, that's all I can describe it as. Its healed. I wouldn't have believed it if I hadn't seen it.–Ferguson Kewley: Diabetic
Any new device that can speed up healing, potentially can help many people who have Diabetic Ulcers.–Dr. Sonia Anand, Associate Professor of Medicine at McMaster University
This one test with the Venowave, showed an unanticipated 50% increase from a normal SPP of 50 to tremendous SPP of 75. If that holds true for others it would be tremendous.–Steven R. Kravitz, DPM, FAPWCA, FACFAS Executive Director, APWCA
I am excited to hear about the Venowave DVT prophylaxis trial because I think this is largely an unmet need since patients have significant compliance issues with SCDs.–Dr. Teresa Carmen, Director of Vascular Medicine at The Cleveland Clinic
Use of the device alone or in combination with ECS was associated with improvement in quality of life and reduced the severity of PTS. The Venowave device is now approved by Health Canada and by the US Food and Drug Administration.–Dr. Susan Khan "How I Treat Postthrombotic Syndrome" Blood Journal of the American Society of Hematology
I recognized the need for a user-friendly out-of-hospital device that pumps blood upward, towards the heart, and which patients would comfortably wear for hours while leading an active lifestyle providing clinicians with impressive results across a range of applications.–John Saringer on how the device was created